|
 |
 |
Dear Friends,
As 2015 winds down and we gear up for 2016, we are thrilled to share with you some exciting news. Thanks to your generous support of January's Part the Cloud Luncheon, which brought us to over $6.4 million raised, we will be funding two additional Part the Cloud human trial research grants — one at Vanderbilt University and the other at the University of Pennsylvania — bringing our number of grants funded to 13! Please refer to the News and Updates section of this email for more information on these grants. We hope you will all share in our excitement as we add these two grants to our funding list. Our goal for the new year is to expand our research funding efforts worldwide, as we continue on our mission to fund Alzheimer's research with the highest probability of slowing, stopping or ultimately curing Alzheimer's disease.
With all of the excitement and momentum surrounding Part the Cloud, we encourage you all to Save the Date for our Part the Cloud Gala, which will be held on April 30, 2016, at the Rosewood Sand Hill in Menlo Park. We hope to see you all there for a fun evening with some Caribbean flair and a very special musical guest. Stay tuned for more in the new year, which is only a few weeks away!
We are humbled and energized by your support and the support of our community as we work to accelerate critically needed research as well as raise awareness about this terrible disease. Together, we will Part the Cloud!
Sincerely,
Mikey Hoag
Founder, Part the Cloud
|
|
 |
|
|
|
|
 |
| |
| |
|
|
 |
New Part the Cloud Grant Recipients
Paul A. Newhouse
Phase 1 Testing of a Muscarinic M1 PAM for Alzheimer's Disease
Vanderbilt University
Newhouse and colleagues will test a novel drug, VU0467319. This novel drug acts on the muscarinic system, a system in the brain that controls cell-cell communication and nerve cell function. As the first drug of this type to be tested in humans, this study will not only advance a potential therapeutic for Alzheimer's but will also open up the door to this entire class of drugs for future exploration. Learn More.
|
 |
Mitchel Kling
A Biomarker-Based Trial of Plasmalogen Repletion in MCI/AD
University of Pennsylvania
Kling and colleagues will conduct a Phase 1 clinical study to investigate the man-made lipid, PPI-1011, a type of plasmalogen. This study will not only advance a potential therapeutic for Alzheimer's into Phase 2 but will also advance our understanding of plasmalogen as a marker of biological significance in Alzheimer's. Learn More. |
|
|
 |
Mikey Hoag and Dagmar Dolby Featured in Women's Initiative Ad
Part the Cloud Founder, Mikey Hoag, and long-time Part the Cloud supporter, Dagmar Dolby, are both featured in the newest Alzheimer’s Association Women’s Initiative ad, out this month. Both women are proud to be using their brains to help bring Alzheimer’s out of the shadows. Learn more. |
|
|
 |
Donate to Support Part the Cloud
This holiday season, please consider making a gift to support Part the Cloud. Your 100% tax-deductible donation will allow us to continue to fund clinical research with the highest probability of slowing, stopping or ultimately curing Alzheimer's disease. Make a donation today. |
|
|
| |
|
|
| |
For questions, please contact info@alz.org
View your email preferences or unsubscribe. |
|
| |
|
|
